Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Chardan Capital Analyst Says

Oculis (NASDAQ:OCS - Free Report) had its price objective hoisted by Chardan Capital from $28.00 to $33.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts also recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research report on Thursday, March 13th. HC Wainwright upped their price objective on shares of Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, April 17th.

Oculis Stock Down 5.3%

Shares of NASDAQ:OCS traded down $0.98 during trading hours on Friday, hitting $17.60. The company's stock had a trading volume of 36,945 shares, compared to its average volume of 43,468. Oculis has a 52 week low of $10.79 and a 52 week high of $23.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The company has a market capitalization of $768.45 million, a price-to-earnings ratio of -9.12 and a beta of 0.27. The firm's fifty day moving average price is $18.01 and its 200 day moving average price is $18.40.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.27). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The firm had revenue of $0.32 million during the quarter, compared to analysts' expectations of $0.22 million. As a group, research analysts expect that Oculis will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

Large investors have recently made changes to their positions in the company. abrdn plc lifted its stake in shares of Oculis by 23.0% in the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after purchasing an additional 188,871 shares during the period. Geode Capital Management LLC lifted its stake in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after purchasing an additional 1,800 shares during the period. XTX Topco Ltd acquired a new position in shares of Oculis in the 4th quarter valued at $225,000. Bellevue Group AG acquired a new position in shares of Oculis in the 4th quarter valued at $170,000. Finally, Kestra Private Wealth Services LLC acquired a new position in shares of Oculis in the 1st quarter valued at $234,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.